Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure: The trials of hypertension prevention, phase II

Archives of Internal Medicine

Volumn 157, Issue 6, 1997, Pages 657-667

  Cutler, Jeffrey A ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG USE; FEMALE; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; PATIENT COUNSELING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SODIUM EXCRETION; SODIUM INTAKE; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION;

EID: 1842365433     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.6.657     Document Type: Article

References (31)

1. Whelton PK, Brancati F, Appel LJ, Klag MJ. The challenge of hypertension and atherosclerotic cardiovascular disease in economically developing countries. High Blood Pressure Cardiovasc Prev. 1995;4:36-45.
2. Whelton PK. Epidemiology of hypertension. Lancet 1994;344:101-106.
3. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993;153:154-183.
4. Hebert P, Moser M, Mayer J, Glynn RJ, Hennekens CH. Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary heart disease. Arch Intern Med. 1993;153:578-581.
5. MacMahon S, Cutler JA, Stamler J, et al. Antihypertensive drug treatment: potential, expected, and observed effects on vascular disease. Hypertension. 1990;335:827-838.
6. Coresh J, Whelton PK, Mead LA, Levine DM, Klag MJ. Increased cardiovascular disease risk in treated hypertensive men. J Hypertens. 1994;12:S73. Abstract.
7. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks: US population data. Arch Intern Med. 1993;153:598-615.
8. Working Group on Primary Prevention of Hypertension. Report of the National High Blood Pressure Education Program Working Group on Primary Prevention of Hypertension. Arch Intern Med. 1993;153:186-208.
9. The Hypertension Prevention Trial Research Group, The Hypertension Prevention Trial (HPT): three-year effects of dietary changes in blood pressure. Arch Intern Med. 1990;150:153-162.
10. Stamler R, Stamler J, Gosch KG, et al. Primary prevention of hypertension by nutritional-hygienic means: final report of a randomized, controlled trial. JAMA. 1989;262:1801-1807.
11. Applegate WB, Borhani NO, Cohen J, et al, for the Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Trials of Hypertension Prevention, Phase I design. Ann Epidemiol. 1991;1:455-471.
12. The Trials of Hypertension Prevention Collaborative Research Group. The effects of non-pharmacological interventions on blood pressure of persons with high normal levels: results of the Trials of Hypertension Prevention (Phase I). JAMA. 1992;267:1213-1220.
13. Stamler R. Implications of the INTERSALT Study. Hypertension. 1991;17 (suppl I);I-16-I-20.
14. Cook NR, Cohen J, Hebert P, Taylor JO, Hennekens CH. Implications of small reductions in diastolic blood pressure for primary prevention. Arch Intern Med. 1995;155:701-709.
15. Hebert PR, Bolt RJ, Borhani NO, et al, for the Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Design of a multicenter trial to evaluate long-term lifestyle intervention in adults with high-normal blood pressure levels: Trials of Hypertension Prevention (Phase II). Ann Epidemiol. 1995;5:130-139.
16. Hollis JF, Satterfield S, Smith F, et al, for the Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Recruitment for Phase II of the Trials of Hypertension Prevention: effective strategies and predictors of randomization. Ann Epidemiol. 1995;5:140-148.
17. Wright BM, Dore CF. A random-zero sphygmomanometer. Lancet. 1970;1:337-338.
18. Metropolitan Life Insurance Co. 1983 Metropolitan height and weight tables. Stat Bull Metrop Life Found. 1983;64:3-9.
19. Lasser VI, Raczynski JM, Stevens VJ, et al, for the Trials of Hypertension Prevention Collaborative Research Group. Trials of Hypertension Prevention, Phase II: structure and content of the weight loss and dietary sodium reduction interventions. Ann Epidemiol. 1995;5:156-164.
20. Stevens VJ, Corrigan SA, Obarzanek E, et al, for the Trials of Hypertension Prevention (TOHP) Collaborative Research Group. Weight loss in Phase I of the Trials of Hypertension Prevention. Arch Intern Med. 1993;153:849-858.
21. Searle SR. Linear Models. New York, NY: John Wiley & Sons Inc; 1971.
22. Cook NR, Ware JH. Design and analysis methods for longitudinal research. Annu Rev Public Health, 1983;4:1-23.
23. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley & Sons Inc; 1980.
24. Appel LJ, Hebert PR, Cohen JD, et al, for the Trials of Hypertension Prevention (TOHP) Collaborative Research Group, Baseline characteristics of participants in Phase II of the Trials of Hypertension (TOHP II). Ann Epidemiol. 1995;5:149-155.
25. Cutler JA, Follmann D, Elliott P, Sun I. An overview of randomized trials of sodium reduction and blood pressure. Hypertension. 1991;17(suppl I):I-27-I-33.
26. Cutler JA. Randomized clinical trials of weight reduction in nonhypertensive persons. Ann Epidemiol. 1991;1:363-370.
27. Elmer PJ, Grimm RH Jr, Flack J, Laing B. Dietary sodium reduction for hypertension prevention and treatment. Hypertension. 1991;17(suppl I):I-182-I-189.
28. Reisin E. Obesity hypertension: nonpharmacologic and pharmacologic therapeutic modalities. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis, and Management. 2nd ed. New York, NY: Raven Press Ltd; 1995.
29. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities: the role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
30. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:202-211.
31. Stamler J. Dietary salt and blood pressure. Ann N Y Acad Sci. 1993;676:122-156.